Literature DB >> 34697091

Inhaled gene therapy of preclinical muco-obstructive lung diseases by nanoparticles capable of breaching the airway mucus barrier.

Namho Kim1,2, Gijung Kwak1,3, Jason Rodriguez1,3, Alessandra Livraghi-Butrico4, Xinyuan Zuo2, Valentina Simon1, Eric Han5, Siddharth Kaup Shenoy1,3, Nikhil Pandey6, Marina Mazur7, Susan E Birket7,8, Anthony Kim6, Steven M Rowe7,8, Richard Boucher4, Justin Hanes1,2,3,9, Jung Soo Suk10,2,3.   

Abstract

INTRODUCTION: Inhaled gene therapy of muco-obstructive lung diseases requires a strategy to achieve therapeutically relevant gene transfer to airway epithelium covered by particularly dehydrated and condensed mucus gel layer. Here, we introduce a synthetic DNA-loaded mucus-penetrating particle (DNA-MPP) capable of providing safe, widespread and robust transgene expression in in vivo and in vitro models of muco-obstructive lung diseases.
METHODS: We investigated the ability of DNA-MPP to mediate reporter and/or therapeutic transgene expression in lung airways of a transgenic mouse model of muco-obstructive lung diseases (ie, Scnn1b-Tg) and in air-liquid interface cultures of primary human bronchial epithelial cells harvested from an individual with cystic fibrosis. A plasmid designed to silence epithelial sodium channel (ENaC) hyperactivity, which causes airway surface dehydration and mucus stasis, was intratracheally administered via DNA-MPP to evaluate therapeutic effects in vivo with or without pretreatment with hypertonic saline, a clinically used mucus-rehydrating agent.
RESULTS: DNA-MPP exhibited marked greater reporter transgene expression compared with a mucus-impermeable formulation in in vivo and in vitro models of muco-obstructive lung diseases. DNA-MPP carrying ENaC-silencing plasmids provided efficient downregulation of ENaC and reduction of mucus burden in the lungs of Scnn1b-Tg mice, and synergistic impacts on both gene transfer efficacy and therapeutic effects were achieved when DNA-MPP was adjuvanted with hypertonic saline. DISCUSSION: DNA-MPP constitutes one of the rare gene delivery systems providing therapeutically meaningful gene transfer efficacy in highly relevant in vivo and in vitro models of muco-obstructive lung diseases due to its unique ability to efficiently penetrate airway mucus. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cystic fibrosis

Mesh:

Substances:

Year:  2021        PMID: 34697091      PMCID: PMC9129924          DOI: 10.1136/thoraxjnl-2020-215185

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.102


  47 in total

1.  Mobility and stability of gene complexes in biogels.

Authors:  Niek N Sanders; Stefaan C De Smedt; Joseph Demeester
Journal:  J Control Release       Date:  2003-02-21       Impact factor: 9.776

2.  Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes.

Authors:  Katsuyuki Mitomo; Uta Griesenbach; Makoto Inoue; Lucinda Somerton; Cuixiang Meng; Eiji Akiba; Toshiaki Tabata; Yasuji Ueda; Gad M Frankel; Raymond Farley; Charanjit Singh; Mario Chan; Felix Munkonge; Andrea Brum; Stefania Xenariou; Sara Escudero-Garcia; Mamoru Hasegawa; Eric W F W Alton
Journal:  Mol Ther       Date:  2010-03-23       Impact factor: 11.454

Review 3.  Barrier properties of mucus.

Authors:  Richard A Cone
Journal:  Adv Drug Deliv Rev       Date:  2008-12-16       Impact factor: 15.470

4.  Membrane topology of the epithelial sodium channel in intact cells.

Authors:  C M Canessa; A M Merillat; B C Rossier
Journal:  Am J Physiol       Date:  1994-12

5.  Transduction of well-differentiated airway epithelium by recombinant adeno-associated virus is limited by vector entry.

Authors:  R Bals; W Xiao; N Sang; D J Weiner; R L Meegalla; J M Wilson
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 6.  The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.

Authors:  Patrick J Moore; Robert Tarran
Journal:  Expert Opin Ther Targets       Date:  2018-07-26       Impact factor: 6.902

7.  Biological Differences in rAAV Transduction of Airway Epithelia in Humans and in Old World Non-human Primates.

Authors:  Xiaoming Liu; Meihui Luo; Cyndi Trygg; Ziying Yan; Diana C M Lei-Butters; Carolina I Smith; Anne C Fischer; Keith Munson; William B Guggino; Bruce A Bunnell; John F Engelhardt
Journal:  Mol Ther       Date:  2007-07-31       Impact factor: 11.454

8.  Revealing the molecular signaling pathways of mucus stasis in cystic fibrosis.

Authors:  Susan E Birket; Steven M Rowe
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

9.  Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung.

Authors:  Aristides D Tagalakis; Mustafa M Munye; Rositsa Ivanova; Hanpeng Chen; Claire M Smith; Ahmad M Aldossary; Luca Z Rosa; Dale Moulding; Josephine L Barnes; Konstantinos N Kafetzis; Stuart A Jones; Deborah L Baines; Guy W J Moss; Christopher O'Callaghan; Robin J McAnulty; Stephen L Hart
Journal:  Thorax       Date:  2018-05-10       Impact factor: 9.139

10.  PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy.

Authors:  Gizem Osman; Jason Rodriguez; Sze Yan Chan; Jane Chisholm; Gregg Duncan; Namho Kim; Amanda L Tatler; Kevin M Shakesheff; Justin Hanes; Jung Soo Suk; James E Dixon
Journal:  J Control Release       Date:  2018-07-03       Impact factor: 11.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.